⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for squamous cell carcinoma of unknown primary

Every month we try and update this database with for squamous cell carcinoma of unknown primary cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take CisplatinNCT03258554
Clinical Stage ...
Head and Neck S...
Hypopharyngeal ...
Laryngeal Squam...
Oral Cavity Squ...
Oropharyngeal S...
Pathologic Stag...
Squamous Cell C...
Stage III Hypop...
Stage III Laryn...
Stage III Lip a...
Stage III Oroph...
Stage IVA Hypop...
Stage IVA Laryn...
Stage IVA Lip a...
Stage IVA Oroph...
Stage IVB Hypop...
Stage IVB Laryn...
Stage IVB Lip a...
Stage IVB Oroph...
Cetuximab
Durvalumab
Intensity-Modul...
Laboratory Biom...
Quality-of-Life...
Questionnaire A...
18 Years - National Cancer Institute (NCI)
Radiation Therapy, Combination Chemotherapy, and Amifostine in Treating Patients With Head and Neck CancerNCT00003582
Carcinoma of Un...
Head and Neck C...
amifostine trih...
cisplatin
fluorouracil
paclitaxel
quality-of-life...
radiation thera...
18 Years - 120 YearsUniversity of Miami
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin CancersNCT02978625
Adenoid Cystic ...
Adnexal Carcino...
Anaplastic Larg...
Anaplastic Larg...
Apocrine Carcin...
Cylindrocarcino...
Digital Papilla...
Endocrine Mucin...
Extramammary Pa...
Extraocular Cut...
Hidradenocarcin...
Keratoacanthoma
Malignant Sweat...
Merkel Cell Car...
Microcystic Adn...
NK-Cell Lymphom...
Papillary Adeno...
Porocarcinoma
Primary Cutaneo...
Recurrent Matur...
Recurrent T-Cel...
Refractory Anap...
Refractory Matu...
Refractory Merk...
Refractory Myco...
Refractory Prim...
Refractory Skin...
Refractory T-Ce...
Sezary Syndrome
Signet Ring Cel...
Skin Basal Cell...
Skin Basosquamo...
Skin Squamous C...
Spiradenocarcin...
Squamoid Eccrin...
Squamous Cell C...
Sweat Gland Car...
Trichilemmal Ca...
Vulvar Squamous...
Biopsy
Biospecimen Col...
Computed Tomogr...
Laboratory Biom...
Nivolumab
Positron Emissi...
Talimogene Lahe...
18 Years - National Cancer Institute (NCI)
Comparing High-Dose Cisplatin Every Three Weeks to Low-Dose Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck CancerNCT05050162
Advanced Head a...
Advanced Hypoph...
Advanced Laryng...
Advanced Oropha...
Squamous Cell C...
Cisplatin
Cisplatin
Quality-of-Life...
Questionnaire A...
Radiation Thera...
18 Years - NRG Oncology
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin CancersNCT02978625
Adenoid Cystic ...
Adnexal Carcino...
Anaplastic Larg...
Anaplastic Larg...
Apocrine Carcin...
Cylindrocarcino...
Digital Papilla...
Endocrine Mucin...
Extramammary Pa...
Extraocular Cut...
Hidradenocarcin...
Keratoacanthoma
Malignant Sweat...
Merkel Cell Car...
Microcystic Adn...
NK-Cell Lymphom...
Papillary Adeno...
Porocarcinoma
Primary Cutaneo...
Recurrent Matur...
Recurrent T-Cel...
Refractory Anap...
Refractory Matu...
Refractory Merk...
Refractory Myco...
Refractory Prim...
Refractory Skin...
Refractory T-Ce...
Sezary Syndrome
Signet Ring Cel...
Skin Basal Cell...
Skin Basosquamo...
Skin Squamous C...
Spiradenocarcin...
Squamoid Eccrin...
Squamous Cell C...
Sweat Gland Car...
Trichilemmal Ca...
Vulvar Squamous...
Biopsy
Biospecimen Col...
Computed Tomogr...
Laboratory Biom...
Nivolumab
Positron Emissi...
Talimogene Lahe...
18 Years - National Cancer Institute (NCI)
Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckNCT04862650
Clinical Stage ...
Metastatic Head...
Metastatic Hypo...
Metastatic Lary...
Metastatic Oral...
Metastatic Orop...
Pathologic Stag...
Recurrent Head ...
Recurrent Hypop...
Recurrent Laryn...
Recurrent Oral ...
Recurrent Oroph...
Squamous Cell C...
Stage IV Hypoph...
Stage IV Laryng...
Stage IV Lip an...
Stage IVA Hypop...
Stage IVA Laryn...
Stage IVA Lip a...
Stage IVB Hypop...
Stage IVB Laryn...
Stage IVB Lip a...
Stage IVC Hypop...
Stage IVC Laryn...
Stage IVC Lip a...
Carboplatin
Cemiplimab
Paclitaxel
18 Years - Ohio State University Comprehensive Cancer Center
Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckNCT04862650
Clinical Stage ...
Metastatic Head...
Metastatic Hypo...
Metastatic Lary...
Metastatic Oral...
Metastatic Orop...
Pathologic Stag...
Recurrent Head ...
Recurrent Hypop...
Recurrent Laryn...
Recurrent Oral ...
Recurrent Oroph...
Squamous Cell C...
Stage IV Hypoph...
Stage IV Laryng...
Stage IV Lip an...
Stage IVA Hypop...
Stage IVA Laryn...
Stage IVA Lip a...
Stage IVB Hypop...
Stage IVB Laryn...
Stage IVB Lip a...
Stage IVC Hypop...
Stage IVC Laryn...
Stage IVC Lip a...
Carboplatin
Cemiplimab
Paclitaxel
18 Years - Ohio State University Comprehensive Cancer Center
Combination Chemotherapy in Treating Patients With Metastatic Cancer of an Unknown Site of OriginNCT00022178
Carcinoma of Un...
cisplatin
cyclophosphamid...
doxorubicin hyd...
epirubicin hydr...
fluorouracil
vincristine sul...
18 Years - National Cancer Institute (NCI)
SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and NeckNCT00006361
Carcinoma of Un...
Head and Neck C...
Non-melanomatou...
semaxanib
18 Years - National Cancer Institute (NCI)
Radiation Therapy in Treating Patients With Metastases to the Lymph Nodes in the Neck From an Unknown Primary TumorNCT00047125
Carcinoma of Un...
radiation thera...
18 Years - 120 YearsEuropean Organisation for Research and Treatment of Cancer - EORTC
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: